Evidence map›Paper›PMID 37087450›Full record

SynthesisBMC medical research methodology2023

Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies.

Humaira Hussein, Keith R Abrams, Laura J Gray, Sumayya Anwer, Sofia Dias, Sylwia Bujkiewicz

Abstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in BMC medical research methodology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. A Review of Methods for Research Synthesis.Statistics in medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Humaira HusseinBiostatistics Research Group, Department of Population Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Keith R AbramsDepartment of Statistics, University of Warwick, Coventry, CV4 7AL, UK.
Laura J GrayBiostatistics Research Group, Department of Population Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Sumayya AnwerCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Sofia DiasCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Sylwia BujkiewiczBiostatistics Research Group, Department of Population Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK. sylwia.bujkiewicz@le.ac.uk.

Funding

Department of HealthMedical Research Council MR/R025223/1
6 · The paper itself

Abstract

backgroundWith the increased interest in the inclusion of non-randomised data in network meta-analyses (NMAs) of randomised controlled trials (RCTs), analysts need to consider the implications of the differences in study designs as such data can be prone to increased bias due to the lack of randomisation and unmeasured confounding. This study aims to explore and extend a number of NMA models that account for the differences in the study designs, assessing their impact on the effect estimates and uncertainty.

methodsBayesian random-effects meta-analytic models, including naïve pooling and hierarchical models differentiating between the study designs, were extended to allow for the treatment class effect and accounting for bias, with further extensions allowing for bias terms to vary depending on the treatment class. Models were applied to an illustrative example in type 2 diabetes; using data from a systematic review of RCTs and non-randomised studies of two classes of glucose-lowering medications: sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

resultsAcross all methods, the estimated mean differences in glycated haemoglobin after 24 and 52 weeks remained similar with the inclusion of observational data. The uncertainty around these estimates reduced when conducting naïve pooling, compared to NMA of RCT data alone, and remained similar when applying hierarchical model allowing for class effect. However, the uncertainty around these effect estimates increased when fitting hierarchical models allowing for the differences in study design. The impact on uncertainty varied between treatments when applying the bias adjustment models. Hierarchical models and bias adjustment models all provided a better fit in comparison to the naïve-pooling method.

conclusionsHierarchical and bias adjustment NMA models accounting for study design may be more appropriate when conducting a NMA of RCTs and observational studies. The degree of uncertainty around the effectiveness estimates varied depending on the method but use of hierarchical models accounting for the study design resulted in increased uncertainty. Inclusion of non-randomised data may, however, result in inferences that are more generalisable and the models accounting for the differences in the study design allow for more detailed and appropriate modelling of complex data, preventing overly optimistic conclusions.

Indexed as

Diabetes Mellitus, Type 2GlucoseGlycated HemoglobinHumansRandomized Controlled Trials as TopicGlucoseGlycated HemoglobinBias adjustmentEvidence synthesisHierarchical modelsReal world evidence

Identifiers

PMID37087450
PMCPMC10122363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.